Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT00290771 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

231

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Recurrent Glioblastoma Multiforme (GBM)

Interventions

DRUG: Imatinib tablets
DRUG: Hydroxyurea capsules

Sponsor

Novartis